Shots:
- XtalPi has entered into a strategic partnership with a biopharmaceutical company to develop an oral small molecule against G protein-coupled receptor
- XtalPi will leverage its structure-based drug design platform, combining quantum physics, generative AI, large-scale automated chemical synthesis orchestrated by a multi-agent system to accelerate Design-Make-Test-Analyze (DMTA) cycles
- As per the deal, XtalPi will receive an upfront payment & full funding for early R&D efforts, with preclinical, clinical, & commercial milestone payments & future royalties, representing the total deal value of over $400M
Ref: PRnewswire | Image: XtalPi |Press Release
Related News: DoveTree Medicines Enters a ~$5.99B Deal with XtalPi to Discover Novel Therapeutics Across Various Indications
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
